Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)

The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) combined with endocrine therapy are established first-line treatments. These agents have significantly improved outcomes for patients with hormone-receptor-positive tumors. However, there is an urgent need for effective later-line treatments. Biomarker-driven therapies, including Menarini’s Orserdu (ESR1-mutant), Novartis’s Piqray (PIK3CA-mutant) and AstraZeneca’s Truqap (PIK3CA/AKT1/PTEN-mutant) have expanded treatment options for metastatic HR-positive / HER2-negative disease. As competition intensifies, novel therapies that address key unmet needs could offer welcome diversification in real-world practice.

QUESTIONS ANSWERED

• What is the level of satisfaction among U.S and European medical oncologists with current treatments for metastatic HR-positive / HER2-negative breast cancer?
• What key factors influence medical oncologists’ decisions when prescribing treatments for metastatic HR-positive / HER2-negative breast cancer? How do key current therapies perform on these key attributes?
• What are the untapped opportunities and unmet needs in this patient subpopulation?
• What trade-offs are U.S. and European oncologists willing to make regarding cost and clinical features for a new metastatic HR-positive / HER2-negative breast cancer drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in March 2026

Key drugs: Ibrance, Kisqali, Verzenio / Verzenios, Piqray, Orserdu, Truqap, everolimus

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

KEY FEATURE

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.